Erythema multiforme major following docetaxel

被引:0
|
作者
Moisidis C. [1 ]
Möbus V. [1 ]
机构
[1] Dept. of Obstetrics and Gynecology, Stadtische Kliniken Frankfurt-H., 65929 Frankfurt
关键词
Docetaxel; Metastatic Breast Cancer; Scleroderma; Skin Reaction; Steven Johnson Syndrome;
D O I
10.1007/s00404-004-0643-9
中图分类号
学科分类号
摘要
Objective: The objective was to report a severe skin reaction, erythema multiforme major, following administration of docetaxel. Case summary: A female patient receiving weekly docetaxel for metastatic breast cancer developed a severe skin reaction characterized by blistering target lesions on her upper and lower extremities as well as painful ulcers of her oropharynx. The diagnosis of erythema multiforme major was made and high-dose hydrocortisone began, with gradual resolution of her symptoms. Discussion: The semi-synthetic taxoid docetaxel, which is increasingly being used in the treatment of breast cancer, has been associated with several adverse skin reactions, including hypersensitivity, nail pigmentation, nail onycholysis, erythrodysethesia, and scleroderma. We report the first case of erythema multiforme major (Stevens-Johnson syndrome) following docetaxel. Erythema multiforme major is a rare inflammatory skin disease associated with certain drugs (i.e., sulfonamides, non-steroidal anti-inflammatory agents, anticonvulsants). It is characterized by a distinguishing target skin lesion and ulceration of mucosal surfaces. In severe cases, systemic manifestations such as pneumonitis can also occur. Treatment involves use of moderate to high-dose corticosteroids. Summary: Clinicians using docetaxel should be aware of the variety of skin reactions that can occur, how they can be avoided and their severity reduced. Severe skin reactions such as occurred with our patient should be recognized and treated promptly in consultation with a dermatologist. © Springer-Verlag 2004.
引用
收藏
页码:267 / 269
页数:2
相关论文
共 50 条
  • [1] ERYTHEMA MULTIFORME MAJOR FOLLOWING USE OF DICLOFENAC
    MORRIS, BAP
    REMTULLA, SS
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1985, 133 (07) : 665 - 665
  • [2] Erythema multiforme major following treatment with infliximab
    Edwards, Dean
    Boritz, Eli
    Cowen, Edward W.
    Brown, Ronald S.
    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 2013, 115 (02): : E36 - E40
  • [3] ERYTHEMA MULTIFORME MAJOR AND MINOR
    YAFFEE, HS
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1984, 10 (03) : 522 - 523
  • [4] CARBAMAZEPINE AND ERYTHEMA MULTIFORME MAJOR
    MCDANAL, CE
    JOURNAL OF CLINICAL PSYCHIATRY, 1988, 49 (09) : 369 - 370
  • [5] Neonatal erythema multiforme major
    Johnston, GA
    Ghura, HS
    Carter, E
    Graham-Brown, RAC
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2002, 27 (08) : 661 - 664
  • [6] Erythema Multiforme Major following SARS-CoV-2 vaccine
    Saibene, Alberto Maria
    Alliata, Andrea
    Cozzi, Anna Teresa
    Ottavi, Alice
    Spagnolini, Sofia
    Pipolo, Carlotta
    Maccari, Alberto
    Felisati, Giovanni
    CLINICAL CASE REPORTS, 2021, 9 (10):
  • [7] Recurrent Erythema Multiforme Major Following COVID-19 Infection
    Rykiel, Kayla
    Melchor, Julian
    Motie, Ian
    Mulles, Kevin
    Farhangi, Vida
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (07)
  • [8] CARBAMAZEPINE AND ERYTHEMA MULTIFORME MAJOR - REPLY
    FAWCETT, RG
    JOURNAL OF CLINICAL PSYCHIATRY, 1988, 49 (09) : 370 - 370
  • [9] Erythema multiforme major induced by tramadol
    Yamada, Masahiro
    Furuta, Miyuki
    Fujimoto, Noriki
    EUROPEAN JOURNAL OF DERMATOLOGY, 2023, 33 (04) : 437 - 439
  • [10] ERYTHEMA MULTIFORME MAJOR AND MINOR - REPLY
    HUFF, C
    WESTON, WL
    TONNESEN, MG
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1984, 10 (03) : 523 - 523